Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Date:9/24/2009

ven adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
4. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
5. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
6. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... N.J. , March 6, 2015  Palatin Technologies, Inc. ... at the 27 th Annual ROTH Conference on Wednesday, ... will be held at the Ritz Carlton Laguna Niguel in ... Carl Spana , Ph.D., President and Chief Executive Officer ... and development programs. About Palatin Technologies, ...
(Date:3/6/2015)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: CNAT ).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On March 5, 2015, the Company abruptly announced in ...
(Date:3/6/2015)... , March 6, 2015  The onset of puberty ... as well as clumsier, and thus more inclined toward a ... during puberty, while the body,s center of gravity is altered. ... hands often grow more quickly than the rest of the ... of height in single year. And while these sudden changes ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Conatus Pharmaceuticals Inc. - CNAT 2Puberty can result in variety of athletic injuries 2
(Date:3/6/2015)... 06, 2015 “On Tap” takes the audience ... grand stage, to the silver screen and to modern day ... toe-tapping numbers and their famous eye-high kicks! Producers, directors and ... history of tap dancing in this robust show, showcasing one ... the United States. , “On Tap” is proud to ...
(Date:3/6/2015)... San Rafael, CA (PRWEB) March 06, 2015 ... the addition of three Maryland camps – two non-contact ... camps will be run by Perfect Performance Training, located ... camps will focus on developing position specific skills, speed ... will be hosted at Salisbury University with Marvin Graves, ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit with ... in Superior Court in the State of California in ... 12 awarded Mrs. Perry $700,000 in actual damages for ... TVT Abbrevo plastic sling for stress urinary incontinence. The ... $5 million in punitive damages. , According to court ...
(Date:3/6/2015)... First Choice Emergency Room opened ... is located at 13351 W. Bowles Avenue, Littleton, Colorado and ... ready 24-7 to provide the highest quality emergency medical care ... of First Choice Emergency Room Littleton. , First ... Metro Denver Chamber of Commerce and a medical community open ...
Breaking Medicine News(10 mins):Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2
... inclination, study finds , WEDNESDAY, June 17 (HealthDay News) -- Bad ... violent street gangs. But a new study finds that the urge ... genes. , Boys who have a variant of the gene monoamine ... are not only more likely to be in gangs than boys ...
... , - SLA Centennial Observance ... Century , Elsevier has been awarded ... BioMedicine and the Life Sciences" at the Special Library,Association,s (SLA) ... published by Elsevier, many on behalf of renowned,societies, were also ...
... in Health and Life Sciences Category , , SUNNYVALE, ... Incorporated (Nasdaq: ARAY ), a global leader in ... the company,s president and CEO, received the Ernst & Young ... Life Sciences category in Northern California. According to Ernst ...
... has begun , , PITTSBURGH, June 17 Mylan ... subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. ... Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This ... and 30 mg strengths of the product. , , ...
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... agreement with Deerfield Management, a leading healthcare investment organization and ... funding through a credit facility. , , "We ... the potential of our business and that we have the ...
... the development of TMC207 and the discovery of new ... 17 A new landmark collaboration between the Global ... product development partnership, and Tibotec Inc., (Tibotec), a global ... Health Summit in response to the urgent need to ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 4Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 2Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Extremely fine straight....
Curved delicate 5 mm blades....
Medicine Products: